Pulmo BioTech Has Revealed That Its PulmoBind(TM) Pulmonary Vascular Diagnostic Product Candidate May Have Particular Applicability to Post Operative Patient Care and Diagnostics
6/29/2010 11:14:53 AM
NEW YORK, June 29, 2010 (GLOBE NEWSWIRE) -- "Pulmonary Embolism (PE) is a potentially fatal condition that occurs when a blood clot forms within the vascular system of the body, becoming detached and then lodged in the pulmonary circulatory system of the lungs. Lung tissue death occurs beyond the embolism and depending on the size of the embolism this can result in conditions ranging from shortness of breath to death. There are many different causes for PE, but one of the times that people are most vulnerable is after surgery. The nature of the surgery itself coupled with post-operative care and reduced mobility can potentially contribute to a patient experiencing PE. If the early experimental results of PulmoBind™ are confirmed by further experiments and clinical trials, then PulmoBind™, which is a simple non-invasive diagnostic test, could be of particular benefit to patients who have undergone surgical intervention." – Garry McCann, CEO, Pulmo BioTech Inc.
comments powered by